Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Medication Response in Children With Predominately Inattentive Type ADHD
Brief Summary: This study evaluates how children with Attention Deficit Disorder without Hyperactivity (ADD) respond to medication, and if their response is different from children who have problems with both hyperactivity and inattention. In order to do this, children ages 7-11 whose primary difficulty is with attention problems and who have never been on behavioral or psychiatric medications are being recruited. Once enrolled, children will try one week each of 3 different doses of methylphenidate, the most commonly prescribed Attention Deficit, Hyperactivity Disorder (ADHD) medication, as well as placebo. Children will be randomly assigned to one of six possible medication dose and placebo titration schedules, but the study doctor, family, and teacher will not know which dose (if any) children are receiving for a given week. Each week, behavioral and side effect ratings will be completed by both the child's parent and teacher, and the family will meet with the study doctor for a physical examination and to discuss how each week went. Some children will also have neuropsychological testing to determine how methylphenidate influences their working memory, sustained attention, and ability to inhibit (stop) inappropriate responses.

All data will be analyzed to decide which medication dose the child responded to best and further recommendations for treatment will be given. Ultimately, this study aims to improve understanding of how children with ADHD-Primarily Inattentive Type respond to stimulant medications by

* determining whether these children experience a diminished response to methylphenidate compared to children with both hyperactivity and inattention
* determining whether certain genetic and environmental factors play a role in this response.

Findings from this study will be used to help streamline the identification of the most effective doses of medication for children with ADHD-Primarily Inattentive Type.


Options:
A: Arm Label: ADHD; Type: N/A; Interventions: N/A
B: Arm Label: OROS-Methylphenidate and placebo for inattentive type pts; Type: OTHER; Interventions: Drug: OROS-Methylphenidate and placebo for inattentive type pts | Arm Label: OROS-Methylphenidate and placebo for combined type pts; Type: OTHER; Interventions: Drug: OROS-Methylphenidate and placebo for combined type pts | Intervention Type: DRUG; Name: OROS-Methylphenidate and placebo for inattentive type pts; Assigned to Arm(s): OROS-Methylphenidate and placebo for inattentive type pts | Intervention Type: DRUG; Name: OROS-Methylphenidate and placebo for combined type pts; Assigned to Arm(s): OROS-Methylphenidate and placebo for combined type pts
C: Arm Label: Adhansia XR; Type: EXPERIMENTAL; Interventions: Drug: Adhansia XR | Arm Label: Concerta; Type: ACTIVE_COMPARATOR; Interventions: Drug: Concerta | Intervention Type: DRUG; Name: Adhansia XR; Assigned to Arm(s): Adhansia XR | Intervention Type: DRUG; Name: Concerta; Assigned to Arm(s): Concerta
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate Transdermal System | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): 1

Answer: B